 | Related Articles |
A BH3 Mimetic for Killing Cancer Cells.
Cell. 2016 Jun 16;165(7):1560
Authors: Green DR
Abstract
Venetoclax is a BH3 mimetic approved for treating chronic lymphocytic leukemia. Cancer cells are resistant to apoptosis but "primed for death" by elevated BCL-2, which binds to pro-apoptotic proteins and holds them in check. Venetoclax releases this antagonism and is the first approved drug to target a protein-protein interaction.
PMID: 27315468 [PubMed - indexed for MEDLINE]
http://ift.tt/2iiJtaX
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου